MHRA Approves Pharming's Joenja for Children with APDS in the U.K.

The U.K. MHRA approved Pharming Group’s Joenja (leniolisib) for children aged 4 to 11 with APDS, expanding its existing approval for older patients. Pharming said it will work with the NHS and other stakeholders to support timely access for eligible children. The announcement did not report financial figures or a stock-price impact.